IGEA PHARMA TO BOOST REVENUES ENTERING THE GROWING CANNABIS MARKET
. The expected revenue stream from the joint venture of CHF63 million along with the additional EUR 4.5 million revenues from other segments will allow IGEA Pharma to be cash positive already by the end of 2022. After the all-equity offer to BSNR being declared unconditional as to acceptances, the Board has approved the new […]
